Daiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan
Daiichi Sankyo aims to transform its antibody-drug conjugate (ADC) leadership into a top global oncology standing. | Daiichi ...
Steps to Check Utkal University UG Provisional Results 2026. Candidates can check their provisional results for various UG courses like B.A, B.Sc, B.Com, and other exams online at the official exam ...
Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to ...
PSEB 10th Result 2026 has been released today at official website pseb.ac.in. Approximately 2 lakh students are eagerly ...
Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular edema (DME) management Oculis is on track to report ...
The right AI PDF reader depends on what you are actually trying to do. A solo researcher checking papers has different needs from a legal team verifying contract clauses, and both have different needs ...
No. 11 / 2026Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight ...
Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patientsOSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE ...
Achieved $51.8 million in RYTELO® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025Reiterated ...
Surveyed HCPs identified reduction of days on TPN as a top priority –– Improved quality of life, lower risk of infection and thrombosis viewed as key benefits of reduced TPN dependence –– Additional ...
Cash position of US$3.1 million as at 31 December 2025. Subsequent to the year end, the Company raised net proceeds of £11.7 million (approximately $15.5 million) through the issuance of 37,878,788 ...
Gilead raised its previous guidance of $800 million in revenues from the long-acting PrEP injectable Yeztugo based on a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results